Evidence for an association between CD23 and the receptor for a low molecular weight B cell growth factor

1986 ◽  
Vol 16 (12) ◽  
pp. 1627-1630 ◽  
Author(s):  
John Gordon ◽  
Adrian J. Webb ◽  
Leonie Walker ◽  
Graeme R. Guy ◽  
Martin Rowe
Keyword(s):  
Molecular Weight ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
Low Molecular Weight ◽  
B Cell Growth Factor

scholarly journals B8.7 antigen is present on B-cell precursor acute lymphocytic leukemia. Correlation with the low molecular weight B-cell growth factor responsiveness of these cells

Blood ◽  
1990 ◽  
Vol 75 (4) ◽  
pp. 963-971 ◽  
Author(s):  
C Leprince ◽  
N Blumenfeld ◽  
G Flandrin ◽  
P Galanaud ◽  
F Sigaux ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
Lymphocytic Leukemia ◽  
Low Molecular Weight ◽  
Dependent Manner ◽  
Cell Precursor ◽  
B Cell Growth Factor ◽  
Human B Cell

Abstract The purpose of this study was to analyze the expression of B8.7 antigen and its implication in the low molecular weight B-Cell growth factor (LMW BCGF) proliferative pathway at the early stages of the human B- cell differentiation. After an overnight incubation in culture medium of B-cell precursor acute lymphoblastic leukemias (ALL), we demonstrated the presence of B8.7 antigen in 18 of 25 cases (72%). Such an incubation also induced a significant increase in the LMW BCGF responsiveness of ALL cells (P less than 0.03). In addition, we showed a significant correlation between B8.7 expression and the ability of pre-B ALL cells to respond to LMW BCGF. As previously described for normal B cells, the anti-B8.7 monoclonal antibody inhibited the LMW BCGF-dependent proliferation of pre-B ALL cells in a dose-dependent manner. These data indicate that B8.7 antigen is expressed and may be functionally related to the LMW BCGF pathway at the pre-B cell stages of differentiation. These results also suggest that human B-cell precursor ALL are not only phenotypically similar to their normal B lymphocyte counterparts, but are also sensitive to the same immunoregulatory cytokines that control normal cell growth.

Activation of the phosphatidylinositol metabolic pathway by low molecular weight B cell growth factor

1988 ◽  
Vol 18 (11) ◽  
pp. 1705-1712 ◽  
Author(s):  
Dominique Renard ◽  
Elisabeth Petit-Koskas ◽  
Elisabeth Gé ◽  
Bernard Dugas ◽  
Josiane Poggioli ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
Metabolic Pathway ◽  
Low Molecular Weight ◽  
B Cell Growth Factor

Response of LFA-l-deficient B cells to interleukin 4 (BSF-1) and low molecular weight B cell growth factor (BCGFlow)

1988 ◽  
Vol 18 (2) ◽  
pp. 255-259 ◽  
Author(s):  
John G. Shields ◽  
Susan H. Smith ◽  
Stephan Strobel ◽  
Roland J. Levinsky ◽  
Thierry Defrance ◽  
...  
Keyword(s):  
Molecular Weight ◽  
B Cells ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
Interleukin 4 ◽  
Low Molecular Weight ◽  
B Cell Growth Factor

scholarly journals B8.7 antigen is present on B-cell precursor acute lymphocytic leukemia. Correlation with the low molecular weight B-cell growth factor responsiveness of these cells

Blood ◽  
1990 ◽  
Vol 75 (4) ◽  
pp. 963-971
Author(s):  
C Leprince ◽  
N Blumenfeld ◽  
G Flandrin ◽  
P Galanaud ◽  
F Sigaux ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
Lymphocytic Leukemia ◽  
Low Molecular Weight ◽  
Dependent Manner ◽  
Cell Precursor ◽  
B Cell Growth Factor ◽  
Human B Cell

The purpose of this study was to analyze the expression of B8.7 antigen and its implication in the low molecular weight B-Cell growth factor (LMW BCGF) proliferative pathway at the early stages of the human B- cell differentiation. After an overnight incubation in culture medium of B-cell precursor acute lymphoblastic leukemias (ALL), we demonstrated the presence of B8.7 antigen in 18 of 25 cases (72%). Such an incubation also induced a significant increase in the LMW BCGF responsiveness of ALL cells (P less than 0.03). In addition, we showed a significant correlation between B8.7 expression and the ability of pre-B ALL cells to respond to LMW BCGF. As previously described for normal B cells, the anti-B8.7 monoclonal antibody inhibited the LMW BCGF-dependent proliferation of pre-B ALL cells in a dose-dependent manner. These data indicate that B8.7 antigen is expressed and may be functionally related to the LMW BCGF pathway at the pre-B cell stages of differentiation. These results also suggest that human B-cell precursor ALL are not only phenotypically similar to their normal B lymphocyte counterparts, but are also sensitive to the same immunoregulatory cytokines that control normal cell growth.

Different human B cell subsets respond to interleukin 2 and to a high molecular weight B cell growth factor (BCGF)

1986 ◽  
Vol 16 (12) ◽  
pp. 1503-1507 ◽  
Author(s):  
Aime Vazquez ◽  
Jean-Philipe Gerard ◽  
Daniel Olive ◽  
Marie-Thérèse Auffredou ◽  
Bernard Dugas ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
High Molecular Weight ◽  
Interleukin 2 ◽  
B Cell Growth Factor ◽  
B Cell Subsets ◽  
Human B Cell

scholarly journals Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti- CD19 immunotoxins

Blood ◽  
1988 ◽  
Vol 71 (1) ◽  
pp. 13-29 ◽  
Author(s):  
FM Uckun ◽  
W Jaszcz ◽  
JL Ambrus ◽  
AS Fauci ◽  
K Gajl-Peczalska ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Monoclonal Antibody ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
Progenitor Cells ◽  
Surface Marker ◽  
Neoplastic Cells ◽  
B Cell Growth Factor ◽  
B Lineage

Abstract Extensive immunologic surface marker analyses and binding competition assays demonstrated that B43 monoclonal antibody (MoAb) is a new member of the CD19 cluster that recognizes the same surface epitope as several other anti-CD19 MoAbs. We used B43 MoAb to test for CD19 expression on neoplastic cells from 340 leukemia and 151 malignant lymphoma patients and on nonneoplastic cells in normal lymphohematopoietic and nonlymphohematopoietic tissues. Our study more than doubles the total number of cases with classified hematologic malignancies that have been examined for CD19 antigen expression. The data presented confirm that CD19 is the most reliable B lineage surface marker and support our view that this B lineage-restricted surface determinant may be an important functional receptor. Our findings provide unique and direct evidence that (a) CD19 is expressed on leukemic B lineage lymphoid progenitor cells freshly obtained from B lineage acute lymphoblastic leukemia patients but not on normal myeloid, erythroid, megakaryocytic, or multilineage bone marrow progenitor cells; (b) ligation of CD19 with B43 MoAb induces sustained increases in [Ca2+]i when crosslinked and inhibits high-molecular weight B cell growth factor (HMW-BCGF)-induced proliferation of activated B cells without affecting their low- molecular weight B cell growth factor (LMW-BCGF) response; therefore CD19 may be a unique signal receptor; (c) HMW-BCGF and LMW-BCGF augment expression of CD19, which suggests that CD19 and BCGF receptors may be under coordinate regulatory control; (d) approximately two million B43 MoAb molecules per cell can be bound to target B lineage lymphoma cells with a Ka of 1.9 x 10(8)/mol/L; (e) CD19 can undergo B43 MoAb-induced internalization; and (f) the opportunity is thus provided for using anti-CD19 MoAb to deliver toxins to B lineage neoplastic cells for more effective treatment of high-risk leukemia/lymphoma patients.

scholarly journals Purification to homogeneity of a high molecular weight human B cell growth factor; demonstration of specific binding to activated B cells; and development of a monoclonal antibody to the factor.

1985 ◽  
Vol 162 (4) ◽  
pp. 1319-1335 ◽  
Author(s):  
J L Ambrus ◽  
C H Jurgensen ◽  
E J Brown ◽  
A S Fauci
Keyword(s):  
Molecular Weight ◽  
Monoclonal Antibody ◽  
B Cells ◽  
Growth Factor ◽  
Cell Growth ◽  
B Cell ◽  
High Molecular Weight ◽  
Sodium Dodecyl ◽  
Western Blots ◽  
B Cell Growth Factor

High molecular weight B cell growth factor (HMW-BCGF) produced by a T cell line was purified to homogeneity and demonstrated to bind specifically to activated human B cells. A monoclonal antibody to HMW-BCGF was developed that (a) specifically inhibited the activity of HMW-BCGF in enhancing B cell proliferation, (b) specifically bound to HMW-BCGF in Western blots, (c) specifically absorbed HMW-BCGF activity from culture supernatants, and (d) specifically absorbed an internally labeled protein from T-ALL supernatant which comigrates with HMW-BCGF on sodium dodecyl sulfate-polyacrylamide gels. This antibody should help in cloning the gene for HMW-BCGF and further exploring the physiologic roles of HMW-BCGF.

Sign in / Sign up

Export Citation Format

Share Document